Despite a 54.6 plunge in operating profits to 64.8 billion won, Samsung SDI's senior fund managers expect a positive business outlook in the second quarter with more ESS orders in the United States and better EV battery demand.
SDI reported 2.39 trillion won in revenue for the three months to March 31, up 4.1 percent year-on-year.
According to one of the fund managers, they expect growth in the second half that would catapult SDI's share price to 390,000 won by the end of this year, up from Friday's closing rate of 286,000 won.
SDI's order backlog for EV batteries is expected to increase by $45 billion in 2020.
While the company's electronic materials division is expected to face more challenges, margins and profits are expected to improve due to increasing demand for OLED and semiconductor materials."
Fund managers also expect revenue from the company's electronic materials and small battery divisions to remain flattish this year.


Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering
Ford and Geely Explore Strategic Manufacturing Partnership in Europe
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning 



